<DOC>
	<DOCNO>NCT01070485</DOCNO>
	<brief_summary>The purpose study investigate multiple ( four ) intravenous injection Xofigo ( Alpharadin ) clinically relevant effect bone marker breast cancer patient bone dominant disease progress endocrine therapy longer consider suitable endocrine therapy . In addition safety Xofigo ( Alpharadin ) assess .</brief_summary>
	<brief_title>BAY88-8223 , Alpharadin , Breast Cancer Patients With Bone Dominant Disease</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Patient female , either postmenopausal ( cessation menses 1 year ) surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy ) therapyinduced premature menopause LHRH agonist . If childbearing potential result urine human chorionic gonadotropin pregnancy test , perform day result know study drug administration , must negative . Histological cytological evidence primary breast cancer . Bone dominant disease ( without metastasis soft tissue , lymph node and/or skin ) least one nonirradiated bone metastasis planar bone scintigraphy/SPECT ± CT within previous 12 week . Patient unequivocally progress endocrine therapy benefit endocrine therapy consider unlikely ( progression must document base image and/or clinically relevant information ) . Patient bisphosphonate therapy least 3 month prior treatment start change bisphosphonate therapy expect treatment phase study , patient treat bisphosphonates , treatment planned start treatment period . Latest endocrine therapy stop least 2 week prior treatment start . ECOG PS 0 2 . Life expectancy ≥6 month . Patient fulfil follow certain laboratory requirement . Received investigational drug within 4 week prior administration Alpharadin , schedule receive one treatment period . Received chemotherapy , immunotherapy , external beam radiation therapy within last 4 week prior administration study drug , recover acute ARs result therapy . Is likely require chemotherapy immunotherapy within 16 week treatment period . Presence imminent establish spinal cord compression base clinical finding and/or MRI . Presence currently active ( relapse within last 3 year ) malignancy ( except nonmelanoma skin cancer ) breast cancer metastasis . Presence unequivocal visceral metastasis require chemotherapy treatment next 6 month , base Investigator 's judgement . Brain metastases allow well control associate symptom . Treatment brain metastasis complete least 8 week prior treatment start . Patients serious illness medical condition , : uncontrolled infection clinical heart failure severe enough cause mark limitation activity , comfortable rest ; heart failure severe ( NYHA Heart Failure Class III IV ) Crohn 's disease ulcerative colitis Bone marrow myelodysplasia Unmanageable faecal incontinence</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>